{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T15:05:44Z","timestamp":1789571144576,"version":"build-2803163510"},"reference-count":70,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":34,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Dermatology"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Dystrophic epidermolysis bullosa (DEB) and junctional EB (JEB) are severe, bullous genodermatoses induced by mutations of genes encoding structural skin proteins that disrupt epidermal adhesion. Until recently, treatment was limited to symptomatic care. Since 2022, three therapies \u2013 birch triterpenes gel (Filsuvez), beremagene geperpavec\u2010svdt (B\u2010VEC, Vyjuvek), and prademagene zamikeracel (pz\u2010cel, Zevaskyn) \u2013 have received regulatory approval, representing the first specific interventions for epidermolysis bullosa. Herein, we provide an overview on their mechanisms of action, efficacy, safety, and clinical implications.<\/jats:p>","DOI":"10.1111\/pde.70223","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T15:58:35Z","timestamp":1788537515000},"page":"20-28","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Update on Approved Therapies for Dystrophic and Junctional Epidermolysis Bullosa"],"prefix":"10.1111","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8949-2552","authenticated-orcid":false,"given":"Alberto","family":"Pappalardo","sequence":"first","affiliation":[{"name":"Department of Dermatology Columbia University Irving Medical Center  New York New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9355-2474","authenticated-orcid":false,"given":"Edward","family":"Eid","sequence":"additional","affiliation":[{"name":"Department of Dermatology Stanford University School of Medicine  Palo Alto California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5328-3284","authenticated-orcid":false,"given":"Rebecca C.","family":"Olsen","sequence":"additional","affiliation":[{"name":"Northwest Medical Center Transitional Year Residency Program  Tucson Arizona USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savannah E.","family":"Bush","sequence":"additional","affiliation":[{"name":"Tulane University School of Medicine  New Orleans Louisiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0474","authenticated-orcid":false,"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[{"name":"Departments of Dermatology, and Pediatrics University of California  San Diego California USA"},{"name":"Rady Children's Hospital  San Diego California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3872-1415","authenticated-orcid":false,"given":"Maria Gnarra","family":"Buethe","sequence":"additional","affiliation":[{"name":"Department of Dermatology University of California Irvine  Irvine California USA"},{"name":"Children's Hospital of Orange County  Orange California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18921"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572\u2010020\u20100210\u20100"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.matbio.2016.07.009"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0963689719857657"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17629"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015149"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1504"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.10.038"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature24487"},{"key":"e_1_2_8_11_1","unstructured":"Krystal Biotech Inc \u201cKrystal Biotech Receives FDA Approval for the First\u2010Ever Redosable Gene Therapy VYJUVEK (Beremagene Geperpavec\u2010Svdt) for the Treatment of Dystrophic Epidermolysis Bullosa \u201d2023 accessed September 2 2025 https:\/\/ir.krystalbio.com\/news\u2010releases\/news\u2010release\u2010details\/krystal\u2010biotech\u2010receives\u2010fda\u2010approval\u2010first\u2010ever\u2010redosable\u2010gene."},{"key":"e_1_2_8_12_1","unstructured":"European Medicines Agency \u201cFilsuvez EPAR Product Information \u201d21 June 2022 https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/filsuvez\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_8_13_1","article-title":"FDA Approves Filsuvez (Birch Triterpenes) for Treatment of Partial\u2010Thickness Wounds in Junctional and Dystrophic Epidermolysis Bullosa","author":"U.S. Food and Drug Administration","year":"2023","journal-title":"Drug Trials Snapshot"},{"key":"e_1_2_8_14_1","unstructured":"VYJUVEK \u201cFDA \u201d2025 September 15 accessed November 14 2025 https:\/\/www.fda.gov\/vaccines\u2010blood\u2010biologics\/vyjuvek."},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000001422"},{"key":"e_1_2_8_16_1","unstructured":"ZEVASKYN \u201cFDA \u201d2025 June 27 https:\/\/www.fda.gov\/vaccines\u2010blood\u2010biologics\/zevaskyn."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1055\/s\u20102006\u2010951723"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1055\/a\u20100850\u20100224"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/burnst\/tkac007"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.31083\/ph.2013.6515"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljac001"},{"key":"e_1_2_8_22_1","article-title":"Filsuvez (Birch Triterpenes) Topical Gel, Prescribing","author":"Amryt Pharmaceuticals DAC","year":"2023","journal-title":"Information"},{"key":"e_1_2_8_23_1","unstructured":"A. G.Birken \u201cOpen Prospective Controlled Randomised Multicenter Phase II Clinical Trial to Compare Intra\u2010Individually the Efficacy and Tolerance of Oleogel\u2010S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites \u201dclinicaltrials.gov 2015 accessed November 15 2025 https:\/\/clinicaltrials.gov\/study\/NCT01294254."},{"key":"e_1_2_8_24_1","unstructured":"\u201cRandomized Multicenter Double Blind Study to Compare the Efficacy and Tolerability of Oleogel\u2010S\u201010 for 3 Months Versus Placebo Only in Patients With Mild to Moderate Actinic Keratoses Located at the Face and Head \u201daccessed November 15 2025 https:\/\/www.clinicaltrialsregister.eu\/ctr\u2010search\/trial\/2008\u2010002632\u201015\/DE."},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13342"},{"key":"e_1_2_8_26_1","unstructured":"A. G.Birken \u201cOpen Blindly Evaluated Prospective Controlled Randomized Multicenter Phase III Clinical Trial to Compare Intra\u2010Individually the Efficacy and Tolerance of Oleogel\u2010S10 Versus Standard of Care in Accelerating the Wound Healing of Split\u2010Thickness Skin Graft Donor Sites \u201dclinicaltrials.gov 2018 accessed November 15 2025 https:\/\/clinicaltrials.gov\/study\/NCT01807650."},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2018.10.019"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.burns.2017.03.005"},{"key":"e_1_2_8_29_1","unstructured":"\u201cEpisalvan | European Medicines Agency (EMA) \u201dMay 30 2018 accessed November 15 2025 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/episalvan."},{"key":"e_1_2_8_30_1","unstructured":"Memorial Sloan Kettering Cancer Center \u201cA Randomized Phase II Double\u2010Blinded Study of the Efficacy of Oleogel\u2010S10 (AP101) Gel for the Treatment of Grade 2\u20103 Radiation Dermatitis in Breast Cancer Patients \u201dclinicaltrials.gov 2025 accessed November 15 2025 https:\/\/clinicaltrials.gov\/study\/NCT05190770."},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/5068969"},{"key":"e_1_2_8_32_1","unstructured":"Amryt Research Limited \u201cDouble\u2010Blind Randomised Vehicle\u2010Controlled Phase III Efficacy and Safety Study With 24\u2010Month Open\u2010Label Follow\u2010up of Oleogel\u2010S10 in Patients With Inherited Epidermolysis Bullosa \u201dclinicaltrials.gov 2023 accessed August 4 2025 https:\/\/clinicaltrials.gov\/study\/NCT03068780."},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf022"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325\u2010023\u201002749\u2010x"},{"key":"e_1_2_8_35_1","unstructured":"Amryt Pharma \u201cA Long\u2010Term Non\u2010Interventional Study to Assess the Incidence of Skin Malignancies in Patients With Dystrophic and Junctional Epidermolysis Bullosa Receiving Treatment With Filsuvez \u201dclinicaltrials.gov 2025 accessed August 4 2025 https:\/\/clinicaltrials.gov\/study\/NCT06423573."},{"key":"e_1_2_8_36_1","unstructured":"United Healthcare \u201cFilsuvez (Birch Triterpenes) Topical Gel. Clinical Pharmacy Prior Authorization Notification and Medical Necessity Requirements \u2013 Commercial \u201daccessed November 17 2025 https:\/\/www.uhcprovider.com\/content\/dam\/provider\/docs\/public\/prior\u2010auth\/drugs\u2010pharmacy\/commercial\/a\u2010g\/PA\u2010Med\u2010Nec\u2010Filsuvez.pdf."},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010023\u201001921\u20105"},{"key":"e_1_2_8_38_1","unstructured":"\u201cVyjuvek | European Medicines Agency (EMA) \u201dFebruary 28 2025 accessed February 15 2026 https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/vyjuvek."},{"key":"e_1_2_8_39_1","unstructured":"\u201cKrystal Biotech Announces Approval of VYJUVEK by Japan's Ministry of Health Labour and Welfare for the Treatment of Dystrophic Epidermolysis Bullosa | Krystal Biotech Inc \u201daccessed February 15 2026 https:\/\/ir.krystalbio.com\/news\u2010releases\/news\u2010release\u2010details\/krystal\u2010biotech\u2010announces\u2010approval\u2010vyjuvekr\u2010japans\u2010ministry."},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2350232"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010022\u201001737\u2010y"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206663"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257\u2010025\u201000942\u2010y"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.17863"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70028"},{"key":"e_1_2_8_46_1","unstructured":"\u201cImpact of Collagen VII Gene Therapy on Squamous Cell Carcinoma Recurrence in Recessive Dystrophic Epidermolysis Bullosa Skin \u201dApril 14 2025 accessed November 18 2025 https:\/\/clinicaltrials.gov\/study\/NCT06731933."},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.36"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2018.00362"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468\u20103083.2011.04205.x"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2301244"},{"key":"e_1_2_8_51_1","unstructured":"Krystal Biotech Inc \u201cA Double\u2010Blind Crossover of KB803 and Matched Placebo for the Treatment and Prevention of Corneal Abrasions in Dystrophic Epidermolysis Bullosa \u201dclinicaltrials.gov 2025 accessed January 5 2026 https:\/\/clinicaltrials.gov\/study\/NCT07016750."},{"key":"e_1_2_8_52_1","unstructured":"\u201cEstimating Costs in Beremagene Geperpavec for Dystrophic Epidermolysis Bullosa\u2014Reply|JAMA Dermatology | JAMA Network \u201daccessed November 14 2025 https:\/\/jamanetwork.com\/journals\/jamadermatology\/article\u2010abstract\/2823305."},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.03.073"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.270.5235.475"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1088547"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200301163480314"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007280"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2021.705019"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108544"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2010.023"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.15588"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.14576"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.08.118"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.03.028"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.130554"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13023\u2010022\u201002546\u20109"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)00778\u20100"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.02.126"},{"key":"e_1_2_8_69_1","unstructured":"read ZSCR 3 min \u201cABEO: Zevaskyn Approved by FDA; Raising Valuation to $11\u2026\u201dYahoo Finance April 30 2025 accessed November 24 2025 https:\/\/finance.yahoo.com\/news\/abeo\u2010zevaskyn\u2010approved\u2010fda\u2010raising\u2010100500085.html."},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/pde.70224"},{"key":"e_1_2_8_71_1","unstructured":"Chiesi USA Inc. FILSUVEZ\u00ae (birch triterpenes) topical gel Prescribing Information. Revised May 2024. [dailymed.nlm.nih.gov]"}],"container-title":["Pediatric Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.70223","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/pde.70223","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pde.70223","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T14:47:45Z","timestamp":1789570065000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pde.70223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":70,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/pde.70223"],"URL":"https:\/\/doi.org\/10.1111\/pde.70223","archive":["Portico"],"relation":{},"ISSN":["0736-8046","1525-1470"],"issn-type":[{"value":"0736-8046","type":"print"},{"value":"1525-1470","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"2025-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}